Background Analysis: US FDA Advisory Committee to Review Cerexa’s Ceftazidime-avibactam for Complicated Infections – DEC 5, 2014 (AIDAC)

The US FDA has scheduled an Anti-Infective Drugs Advisory Committee (AIDAC) Meeting for Friday, December 5, 2014 to discuss new drug application 206494 for ceftazidime-avibactam for injection, submitted by Cerexa Inc., for the proposed indications of: Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, including Acute Pyelonephritis and Limited Use Indication: Aerobic Gram-negative Infections with Limited Treatment Options.

See the SAC Tracker Report